IPSC-derived immune cells in prevention and treatment of age-related and neurodegenerative diseases

• Main Authors: GOODRICH HELEN, SVENDSEN CLIVE NILS, MOSER VANESSA ALEXANDRA, LAPPEL ALEXANDER
• Format: Patent
• Language: Chinese; English
• Published: 04.06.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Mononuclear phagocytes derived from induced pluripotent stem cells are represented as iMPs, comprising monocytes generated from induced pluripotent stem cells and optionally further comprising macrophages generated from induced pluripotent stem cells, provided for improving cognitive function, improving neural health, and/or alleviating or treating neurodegenerative disorders in a mammal. In various embodiments, the iMP produces macrophages and/or expresses macrophage markers after transplantation or after stimulation in vitro. We demonstrate that iMP improves cognitive and neurological health after administration in rodent models of aging, Alzheimer's disease, and amyotrophic lateral sclerosis. Also provided are methods of treatment using mononuclear phagocytes generated from autologous stem cells or from induced pluripotent stem cells obtained from autologous cells in a patient in need of treatment or prevention of a neurodegenerative disorder. 源自诱导多能干细胞的单核吞噬细胞被表示为iMP，其包括由诱导多能干细胞生成的单核细胞并任选地进一步包括由诱导多能干细胞生成的巨